Literature DB >> 18360827

Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma.

Volker Ehemann1, Michael A Kern, Marco Breinig, Philipp A Schnabel, Bastian Gunawan, Hans-Jörg Schulten, Christoph Schlaeger, Bernhard Radlwimmer, Christina M Steger, Hendrik Dienemann, Peter Lichter, Peter Schirmacher, Ralf J Rieker.   

Abstract

Thymomas and thymic carcinomas are peculiar epithelial tumors of the anterior mediastinum. They may show aggressive clinical behavior and are a paradigm for the interaction between the tumor and the immune system. So far, adequate functional studies enabling a better understanding of this malignancy have not been performed, since human thymoma/thymic carcinoma cell lines have not been available. Here, the authors describe the establishment, characterization and functional analyses of epithelial cell lines from a Type B1-thymoma and a poorly differentiated thymic carcinoma. By Fluorescence-activated cell sorting (FACS) analyses, both cell lines were aneuploid. The aneuploid cell fraction of the thymic carcinoma cell line was characterized by a high proliferation index of 55.9%, in contrast to a lower proliferation rate of the aneuploid cell fraction of the thymoma (19.7%). Array-based comparative genomic hybridization (aCGH) and conventional cytogenetic analysis of the thymoma revealed only minor imbalances whereas the thymic carcinoma was characterized by a complex karyotype in the hyperdiploid range that was readily defined with multicolor FISH (mFISH). Application of a selective COX-2 inhibitor reduced cell viability in both cell lines in a dose-dependent manner. In conclusion, these first cell lines of a thymoma and a CD5-positive thymic carcinoma are useful tools for further in vitro studies of cellular, molecular and genetic aspects of the disease and for functional tests to evaluate new therapeutic targets. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18360827     DOI: 10.1002/ijc.23335

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

Authors:  Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

2.  Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.

Authors:  Ronan T Swords; Diana Azzam; Hassan Al-Ali; Ines Lohse; Claude-Henry Volmar; Justin M Watts; Aymee Perez; Ana Rodriguez; Fernando Vargas; Roy Elias; Francisco Vega; Arthur Zelent; Shaun P Brothers; Taher Abbasi; Jonathan Trent; Shaukat Rangwala; Yehuda Deutsch; Eibhlin Conneally; Leylah Drusbosky; Christopher R Cogle; Claes Wahlestedt
Journal:  Leuk Res       Date:  2017-11-11       Impact factor: 3.156

3.  LINC00174 is a novel prognostic factor in thymic epithelial tumors involved in cell migration and lipid metabolism.

Authors:  Claudia Tito; Federica Ganci; Andrea Sacconi; Silvia Masciarelli; Giulia Fontemaggi; Claudio Pulito; Enzo Gallo; Valentina Laquintana; Alessia Iaiza; Luciana De Angelis; Anna Benedetti; Jessica Cacciotti; Selenia Miglietta; Maria Bellenghi; Alessandra Carè; Alessandro Fatica; Daniele Diso; Marco Anile; Vincenzo Petrozza; Francesco Facciolo; Gabriele Alessandrini; Edoardo Pescarmona; Federico Venuta; Mirella Marino; Giovanni Blandino; Francesco Fazi
Journal:  Cell Death Dis       Date:  2020-11-07       Impact factor: 8.469

4.  Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.

Authors:  Teresa Bellissimo; Federica Ganci; Enzo Gallo; Andrea Sacconi; Claudia Tito; Luciana De Angelis; Claudio Pulito; Silvia Masciarelli; Daniele Diso; Marco Anile; Vincenzo Petrozza; Felice Giangaspero; Edoardo Pescarmona; Francesco Facciolo; Federico Venuta; Mirella Marino; Giovanni Blandino; Francesco Fazi
Journal:  Mol Cancer       Date:  2017-05-10       Impact factor: 27.401

5.  Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.

Authors:  Fabio Conforti; Xu Zhang; Guanhua Rao; Tommaso De Pas; Yoko Yonemori; Jose Antonio Rodriguez; Justine N McCutcheon; Raneen Rahhal; Anna T Alberobello; Yisong Wang; Yu-Wen Zhang; Udayan Guha; Giuseppe Giaccone
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

6.  Expression and mutational status of c-kit in thymic epithelial tumors.

Authors:  Iacopo Petrini; Paolo A Zucali; Hye Seung Lee; Marbin A Pineda; Paul S Meltzer; Beatriz Walter-Rodriguez; Massimo Roncalli; Armando Santoro; Yisong Wang; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2010-09       Impact factor: 15.609

7.  Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.

Authors:  Iacopo Petrini; Yisong Wang; Paolo A Zucali; Hye Seung Lee; Trung Pham; Donna Voeller; Paul S Meltzer; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

8.  Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.

Authors:  Xiao-Feng Li; Qiang Chen; Wei-Xian Huang; Yun-Bin Ye
Journal:  Med Oncol       Date:  2008-10-10       Impact factor: 3.064

9.  PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.

Authors:  Anna Teresa Alberobello; Yisong Wang; Frans Joseph Beerkens; Fabio Conforti; Justine N McCutcheon; Guanhua Rao; Mark Raffeld; Jing Liu; Raneen Rahhal; Yu-Wen Zhang; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2016-04-24       Impact factor: 15.609

10.  Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.

Authors:  I Petrini; P S Meltzer; P A Zucali; J Luo; C Lee; A Santoro; H S Lee; K J Killian; Y Wang; M Tsokos; M Roncalli; S M Steinberg; Y Wang; G Giaccone
Journal:  Cell Death Dis       Date:  2012-07-19       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.